Posted by Michael Wonder on 02 May 2019
SMA patients in Saskatchewan, Canada, gain wider access to Spinraza
1 May 2019 - The Canadian province of Saskatchewan has joined that of Quebec in granting access to Spinraza (nusinersen) therapy to a wider range of people with spinal muscular atrophy, Biogen Canada announced in a press release.
Only those with type 1 spinal muscular atrophy, the disease’s most severe form, had access to Spinraza.
Now, the Saskatchewan Ministry of Health has decided to expand coverage to pre-symptomatic patients who have two or three copies of the SMN2 gene, and patients up to age 18 who developed symptoms after they were 6 months old and who have never walked independently.
